Trials / Completed
CompletedNCT02277600
A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
Open-Label, Single-Sequence, Two-Cohort Study to Evaluate the Effect of Darunavir/Cobicistat and Cobicistat on BMS-626529 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label, single sequence, 2-cohort, drug-drug interaction study in healthy male and female subjects. There is no formal hypothesis, however, it is expected that the coadministration of BMS-663068 with darunavir (DRV)/cobicistat (COBI) or COBI will increase the systemic exposure of BMS-626529.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-663068 | BMS-663068 |
| DRUG | Darunavir | Darunavir |
| DRUG | Cobicistat | Cobicistat |
Timeline
- Start date
- 2014-11-05
- Primary completion
- 2015-01-12
- Completion
- 2015-01-12
- First posted
- 2014-10-29
- Last updated
- 2018-01-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02277600. Inclusion in this directory is not an endorsement.